Tower Research Capital LLC (Trc) Uro Gen Pharma Ltd. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,290 shares of URGN stock, worth $31,385. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,290
Previous 6,891
81.28%
Holding current value
$31,385
Previous $94,000
73.4%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding URGN
# of Institutions
171Shares Held
43.8MCall Options Held
1.61MPut Options Held
433K-
Rtw Investments, LP New York, NY4.54MShares$111 Million1.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.22MShares$103 Million2.65% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$77.6 Million0.1% of portfolio
-
Morgan Stanley New York, NY2.53MShares$61.5 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$53.5 Million0.21% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $553M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...